Daré Bioscience, Inc. (DARE)
0.4074
-0.04
(-9.86%)
USD |
NASDAQ |
Nov 20, 16:00
0.4092
0.00 (0.00%)
After-Hours: 20:00
Daré Bioscience Enterprise Value : 3.283M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 3.283M |
| November 19, 2026 | 4.159M |
| November 18, 2026 | 4.120M |
| November 17, 2026 | 3.707M |
| November 16, 2026 | 6.760M |
| November 13, 2026 | 8.199M |
| November 12, 2026 | 7.940M |
| November 11, 2026 | 8.921M |
| November 10, 2026 | 8.882M |
| November 09, 2026 | 8.644M |
| November 06, 2026 | 7.837M |
| November 05, 2026 | 7.542M |
| November 04, 2026 | 8.288M |
| November 03, 2026 | 8.054M |
| November 02, 2026 | 8.152M |
| October 30, 2026 | 9.029M |
| October 29, 2026 | 8.673M |
| October 28, 2026 | 8.644M |
| October 27, 2026 | 8.309M |
| October 26, 2026 | 7.932M |
| October 23, 2026 | 7.973M |
| October 22, 2026 | 8.087M |
| October 21, 2026 | 8.801M |
| October 20, 2026 | 8.821M |
| October 19, 2026 | 9.155M |
| Date | Value |
|---|---|
| October 16, 2026 | 9.521M |
| October 15, 2026 | 9.824M |
| October 14, 2026 | 9.608M |
| October 13, 2026 | 9.975M |
| October 12, 2026 | 10.02M |
| October 09, 2026 | 10.48M |
| October 08, 2026 | 10.46M |
| October 07, 2026 | 10.81M |
| October 06, 2026 | 11.66M |
| October 05, 2026 | 11.85M |
| October 02, 2026 | 11.85M |
| October 01, 2026 | 12.01M |
| September 30, 2026 | 12.05M |
| September 29, 2026 | 6.510M |
| September 28, 2026 | 5.524M |
| September 25, 2026 | 5.911M |
| September 24, 2026 | 5.380M |
| September 23, 2026 | 6.395M |
| September 22, 2026 | 7.041M |
| September 21, 2026 | 6.434M |
| September 18, 2026 | 6.044M |
| September 17, 2026 | 5.491M |
| September 16, 2026 | 5.152M |
| September 15, 2026 | 5.222M |
| September 14, 2026 | 5.316M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Omeros Corp. | 1.180B |
| Aytu BioPharma, Inc. | 20.95M |
| ANI Pharmaceuticals, Inc. | 1.741B |
| Corcept Therapeutics, Inc. | 6.596B |
| Veru, Inc. | 9.969M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.158M |
| Revenue (Quarterly) | 0.0476M |
| Total Expenses (Quarterly) | 3.206M |
| EPS Diluted (Quarterly) | -0.1813 |
| Gross Profit Margin (Quarterly) | -1.64K% |
| Profit Margin (Quarterly) | -6.63K% |
| Earnings Yield | -168.8% |
| Normalized Earnings Yield | -168.76 |